<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01160848</url>
  </required_header>
  <id_info>
    <org_study_id>PC TA205/10</org_study_id>
    <nct_id>NCT01160848</nct_id>
  </id_info>
  <brief_title>Photoactive Porphyrins (PAP) Levels After Topical Visonac Application in Acne Patients</brief_title>
  <official_title>A Clinical Study of Photoactive Porphyrins (PAP) Levels in Acne-affected Skin After Topical Visonac Application in Patients With Moderate to Severe Facial Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Photocure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Photocure</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, prospective, randomized, single-centre study in patients with moderate to severe facial
      acne vulgaris. Three circular areas with a diameter of 4 cm, each circle including at least 4
      inflammatory lesions, will be selected in acne-affected areas in the face. One area should be
      identified on each cheek and one area should be identified on the forehead. The minimum
      distance between the three areas should be at least 4 cm. For each patient the three areas
      will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl
      alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before
      application of the Visonac cream. One of the areas cleaned with saline wipe will also be
      occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo
      fluorescence spectroscopy will be performed in the three areas before cream application, and
      at 1h, 1.5h, 2h, 2.5h and 3 h after cream application. After the last fluorescence
      spectroscopy reading, the cream should be wiped off and the patient should protect the three
      areas from sunlight, prolonged, or intense light for 2 days.

      The study was extended with additionally 8 patients to explore the photoactive porphyrin
      levels over a 24 hour period:

      The patients will clean their face with Cetaphil Gentle Skin Cleanser before cream
      application. For each patient the three areas will be randomized to Visonac 80mg left on the
      skin for 24 hours and Visonac (MAL8%) to be wiped of after 1 hour.

      In vivo fluorescence spectroscopy will be performed at all three areas before cream
      application, and at 2h, 3 h, 4h, 5h, 8h, 10h, 11h, 12h, 13h, 15 and 24h after cream
      application. The exact time points may be adjusted based on the result from the previously
      included patients. All patients will be instructed to protect the three areas from sunlight,
      prolonged, or intense light for 2 days.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>1.5 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>3 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>3 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>8 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>12 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Photoactive Porphyrins Level</measure>
    <time_frame>24 hours after cream application</time_frame>
    <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Three areas will be randomized to either a pre-treatment cleaning using a wipe containing an ethyl alcohol solution(one area) or a cleansing wipe containing saline water (two areas), before application of the Visonac cream. One of the areas cleaned with saline wipe will also be occluded with a transparent dressing (Tegaderm) during the incubation time. In vivo fluorescence spectroscopy will be performed in the three areas before cream application, and at 1h, 1.5h, 2h, 2.5h and 3 h after cream application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>For each patient, 3 areas were randomized to treatment with Visonac for 24 hours (2 areas) or Visonac for 1 hour (1 area)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Area cleaned with saline water and occluded with Tegaderm</intervention_name>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Area cleaned with saline water</intervention_name>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Area cleaned with Ethyl alcohol solution</intervention_name>
    <arm_group_label>Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visonac left on the skin for 24 hours in facial area one</intervention_name>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visonac wiped off after one hour</intervention_name>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Visonac left on the skin 24 hours in facial area two</intervention_name>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and verified informed consent form. For patients under age of 18, an assent
             form in conjunction with an informed consent form, signed and verified by
             parent/guardian.

          -  Adolescent and adult female and male patients, from 12 to 35 years of age.

          -  Patients with moderate to severe facial acne vulgaris according to the IGA scale.

          -  Female patients who are surgically sterile, pre-menstrual, postmenopausal, abstinent,
             or willing to use an adequate means of contraception including birth control pills, or
             barrier methods and spermicide for at least 14 days prior to the study visit.

          -  Patients with skin type II to III (Fitzpatrick).

          -  Patients with 3 areas of 4 cm in diameter, each including at least with at least 4
             inflammatory lesions (papules, pustules, and nodules) in the face (at cheek and
             forehead).

        Exclusion Criteria:

          -  Subject is the investigator or any sub investigator, research assistant, pharmacist,
             study coordinator, other staff or relative thereof directly involved in the conduct of
             the protocol.

          -  Patients unlikely to comply with the protocol, e.g. mental condition rendering the
             patient unable to understand the nature, scope, and possible consequences of the
             clinical study, uncooperative attitude or unlikelihood of completing the study (e.g.
             drug or alcohol abuse).

          -  Female subjects with childbearing potential (i.e. ovulation, pre-menopausal, not
             surgically sterilized) not willing to use a medically accepted contraceptive regimen
             while on treatment.

          -  Pregnancy

          -  Lactating.

          -  Participation in other clinical studies either currently or within the last 30 days.

          -  Patients with porphyria.

          -  Known allergy to (MAL), to a similar PDT compound, or to excipients of the cream

          -  Patients with cutaneous photosensitivity.

          -  Patients that have received topical treatments for their acne within the last 14 days.
             Medicated cleansers not containing active ingredients such as 5% BPO or high
             concentration of salicylic acid may be stopped before the treatment. (Cosmetic
             Cleansers that contains no more than 2 % salicylic acid is allowed).

          -  Patients that has received oral antibiotics for treatment of their acne within the
             last month.

          -  Patients that has received oral isotretinoin within the last 6 months.

          -  Patients with a beard that might interfere with study assessments.

          -  Patients with melanoma or dysplastic nevi in the treatment area
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael T. Jarratt, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>DermResearch, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2010</study_first_submitted>
  <study_first_submitted_qc>July 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2010</study_first_posted>
  <results_first_submitted>October 22, 2013</results_first_submitted>
  <results_first_submitted_qc>April 22, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2014</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Moderate to severe Acne Vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted in one center in the US:
Michael Jarratt M.D. DermResearch Inc. 8140 N Mopac Building 3, Suite 120 Austin, TX 78759. First patient entered the study on the 8th of November 2010 Last patient last visit on the 9th January 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>3 Areas Per Patient, 3 Hours</title>
          <description>Visonac : MAL 80 mg/g Group 1: Alcohol wipe and Visonac without occlusion Group 2: Saline wipe and Visonac with occlusion Group 3: Saline wipe and Visonac without occlusion</description>
        </group>
        <group group_id="P2">
          <title>3 Areas Per Patient, 24 Hours</title>
          <description>Group 1: Visonac left on skin for 1 hour Group 2: Visonac left on skin for 24 hours, area 1 Group 3: Visonac left on skin for 24 hours, area 2</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>3 Areas Per Patient, 3 Hours</title>
        </group>
        <group group_id="B2">
          <title>3 Areas Per Patient, 24 Hours</title>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fluoresence intensity</title>
          <description>In the study arm &quot;3 Areas Per Patient, 3 Hours&quot;, participants were only treated with &quot;Alcohol wipe and Visonac without occlusion&quot;, &quot;Saline wipe and Visonac with occlusion&quot;, &quot;Saline wipe and Visonac without occlusion&quot;.
In the study arm &quot;3 Areas Per Patient, 24 Hours&quot; participants were only treated with &quot;Visonac left on skin for 1 hour&quot;, &quot;Visonac left on skin for 24 hours, area 1&quot;, &quot;Visonac left on skin for 24 hours, area 2&quot;.</description>
          <units>Fluoresence intensity unit</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <title>Alcohol wipe and Visonac without occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.5" spread="5.0" lower_limit="4" upper_limit="17.5"/>
                    <measurement group_id="B2" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B3" value="10.5" lower_limit="4" upper_limit="17.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saline wipe and Visonac with occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11.2" lower_limit="5" upper_limit="28"/>
                    <measurement group_id="B2" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B3" value="11.2" lower_limit="5" upper_limit="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Saline wipe and Visonac without occlusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10.8" lower_limit="5" upper_limit="17"/>
                    <measurement group_id="B2" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B3" value="10.8" lower_limit="5" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visonac left on skin for 1 hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B2" value="9.3" lower_limit="3" upper_limit="20.5"/>
                    <measurement group_id="B3" value="9.3" lower_limit="3" upper_limit="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visonac left on skin for 24 hours, area 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B2" value="10.5" lower_limit="4" upper_limit="19.5"/>
                    <measurement group_id="B3" value="10.5" lower_limit="4" upper_limit="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visonac left on skin for 24 hours, area 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Participants in this study arm were not provided this treatment, please see Baseline Measure Description.</measurement>
                    <measurement group_id="B2" value="10.6" lower_limit="4" upper_limit="21"/>
                    <measurement group_id="B3" value="10.6" lower_limit="4" upper_limit="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>1.5 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Area Cleaned With Saline and Occluded With Tegaderm</title>
          </group>
          <group group_id="O2">
            <title>Area Cleaned With Saline</title>
          </group>
          <group group_id="O3">
            <title>Area Cleaned With Ethyl Alcohol Solution</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="24.8" upper_limit="41.3"/>
                    <measurement group_id="O2" value="24.8" lower_limit="20.4" upper_limit="29.1"/>
                    <measurement group_id="O3" value="19.7" lower_limit="15.2" upper_limit="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>3 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Part 1: Area Cleaned With Saline and Occluded With Tegaderm</title>
          </group>
          <group group_id="O2">
            <title>Area Cleaned With Saline</title>
          </group>
          <group group_id="O3">
            <title>Area Cleaned With Ethyl Alcohol Solution</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 1, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="45.4" upper_limit="73.2"/>
                    <measurement group_id="O2" value="38.3" lower_limit="31.6" upper_limit="45.1"/>
                    <measurement group_id="O3" value="30.1" lower_limit="23.2" upper_limit="37.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>3 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Wiped Off After 1 Hour</title>
          </group>
          <group group_id="O2">
            <title>Visonac Left on Skin for 24 Hours in Area 1</title>
          </group>
          <group group_id="O3">
            <title>Visonac Left on Skin for 24 Hours in Area 2</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.3" lower_limit="16.4" upper_limit="54.1"/>
                    <measurement group_id="O2" value="33.5" lower_limit="20.4" upper_limit="46.6"/>
                    <measurement group_id="O3" value="37.3" lower_limit="21.4" upper_limit="53.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>8 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Wiped Off After 1 Hour</title>
          </group>
          <group group_id="O2">
            <title>Visonac Left on Skin for 24 Hours in Area 1</title>
          </group>
          <group group_id="O3">
            <title>Visonac Left on Skin for 24 Hours in Area 2</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" lower_limit="12.4" upper_limit="30.8"/>
                    <measurement group_id="O2" value="38.2" lower_limit="23.1" upper_limit="53.3"/>
                    <measurement group_id="O3" value="44.3" lower_limit="24.6" upper_limit="64.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>12 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Wiped Off After 1 Hour</title>
          </group>
          <group group_id="O2">
            <title>Visonac Left on Skin for 24 Hours in Area 1</title>
          </group>
          <group group_id="O3">
            <title>Visonac Left on Skin for 24 Hours in Area 2</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.8" lower_limit="11.8" upper_limit="21.8"/>
                    <measurement group_id="O2" value="33.9" lower_limit="23.5" upper_limit="44.4"/>
                    <measurement group_id="O3" value="38.1" lower_limit="21.8" upper_limit="54.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Photoactive Porphyrins Level</title>
        <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
        <time_frame>24 hours after cream application</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Visonac Wiped Off After 1 Hour</title>
          </group>
          <group group_id="O2">
            <title>Visonac Left on Skin for 24 Hours in Area 1</title>
          </group>
          <group group_id="O3">
            <title>Visonac Left on Skin for 24 Hours in Area 2</title>
          </group>
        </group_list>
        <measure>
          <title>Photoactive Porphyrins Level</title>
          <description>Photoactive porphyrins levels on the skin surface of acne patients, part 2, measured by in vivo fluorescence spectroscopy</description>
          <units>Fluorescence intensity unit</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.1" lower_limit="8.5" upper_limit="17.7"/>
                    <measurement group_id="O2" value="25.8" lower_limit="17.0" upper_limit="34.6"/>
                    <measurement group_id="O3" value="25.9" lower_limit="17.6" upper_limit="34.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>3 Areas Per Patient, 3 Hours</title>
        </group>
        <group group_id="E2">
          <title>3 Areas Per Patient, 24 Hours</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="12"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Increased number of pimples</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Burning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Project Director</name_or_title>
      <organization>Photocure ASA</organization>
      <phone>+47 22062210</phone>
      <email>pf@photocure.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

